

Risa Kagan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5662647/publications.pdf>

Version: 2024-02-01

18
papers

810
citations

840119

11
h-index

839053

18
g-index

18
all docs

18
docs citations

18
times ranked

704
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. <i>Fertility and Sterility</i> , 2009, 92, 1045-1052.	0.5	212
2	A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. <i>Menopause</i> , 2010, 17, 281-289.	0.8	171
3	Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. <i>Menopause</i> , 2018, 25, 596-608.	0.8	143
4	Why the product labeling for low-dose vaginal estrogen should be changed. <i>Menopause</i> , 2014, 21, 911-916.	0.8	63
5	Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause. <i>Drugs and Aging</i> , 2019, 36, 897-908.	1.3	60
6	Efficacy and safety of erenumab in women with a history of menstrual migraine. <i>Journal of Headache and Pain</i> , 2020, 21, 95.	2.5	30
7	Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials. <i>Journal of Women's Health</i> , 2016, 25, 431-442.	1.5	25
8	The Tissue Selective Estrogen Complex: A Novel Approach to the Treatment of Menopausal Symptoms. <i>Journal of Women's Health</i> , 2012, 21, 975-981.	1.5	23
9	Current and Evolving Approaches to Individualizing Estrogen Receptor-Based Therapy for Menopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 733-747.	1.8	22
10	Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2703-2714.	0.9	17
11	Safety and benefit considerations for menopausal hormone therapy. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 941-954.	1.0	14
12	Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms. <i>Menopause</i> , 2019, 26, 513-519.	0.8	10
13	Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 549.	0.9	7
14	Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal women. <i>Menopause</i> , 2016, 23, 1204-1213.	0.8	5
15	Restoring vaginal function in postmenopausal women with genitourinary syndrome of menopause. <i>Menopause</i> , 2018, 25, 106-108.	0.8	3
16	Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo. <i>Postgraduate Medicine</i> , 2018, 130, 687-693.	0.9	3
17	SAT-237 Combined Bioidentical Estradiol and Progesterone Capsules Improved Quality of Sleep in Postmenopausal Women with Vasomotor Symptoms. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	1
18	Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms. <i>Menopause</i> , 2022, 29, 304-308.	0.8	1